FDA Approval, Quarterly Reports, Event, and Licensing Agreement - Research Report on Novo Nordisk, DexCom, Theravance, PDL, and WuXi PharmaTech
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 12, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Novo Nordisk A/S (NYSE: NVO), DexCom, Inc. (NASDAQ: DXCM), Theravance Inc. (NASDAQ: THRX), PDL BioPharma, Inc. (NASDAQ: PDLI), and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Novo Nordisk A/S Research Report
On November 1,2 013, Novo Nordisk A/S (Novo Nordisk) announced that the US Food and Drug Administration (FDA) has approved the prefilled insulin pens NovoRapid FlexTouch and Levemir FlexTouch. Novo Nordisk also reported that Levemir FlexTouch has just been approved by the Canadian health authorities, Health Canada. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, stated, "Novo Nordisk is committed to continuously developing new and better solutions within insulin delivery, and this approval is an important milestone in the efforts to make the lives of people with diabetes easier." The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO]
--
DexCom, Inc. Research Report
On November 6, 2013, DexCom, Inc. (DexCom) released its Q3 2013 results. DexCom registered total revenues of $42.9 million, up approximately 85.7% YoY in Q3 2013. The Company posted net loss of $6.0 million in Q3 2013, compared to net loss of $17.3 million in Q3 2012. DexCom reported diluted loss per share of $0.08 in Q3 2013, compared to diluted loss per share of $0.25 in Q3 2012. The Full Research Report on DexCom, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/d377_DXCM]
--
Theravance Inc. Research Report
On October 29, 2013, Theravance Inc. (Theravance) announced that Rick E. Winningham, Theravance's CEO, will present during the 2013 Credit Suisse Annual Health Care Conference on Wednesday, November 13, 2013, at 9:30 a.m. MST. Theravance reported that the event will be held from November 11, 2013 to November 14, 2013 at the Phoenician Hotel in Scottsdale, Arizona. The Company informed that interested parties may access the live webcast through its Investor Relations website. The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fa70_THRX]
--
PDL BioPharma, Inc. Research Report
On November 6, 2013, PDL BioPharma, Inc. (PDL) released its Q3 2013 results. PDL registered total revenues of $97.3 million in Q3 2013, up 14.2% YoY. The Company posted net income of $56.2 million in Q3 2013, up 15.7% YoY. PDL reported diluted EPS of $0.36 in Q3 2013, up 12.5% YoY. Commenting on the results, John P. McLaughlin, President and CEO of PDL, said, "We are gratified by the continued success of our asset acquisition strategy, including the four additional transactions completed in the past month, and believe that-with ROI at top-of-mind-we are continuing to add long term value for the company and our stockholders." McLaughlin continued, "Our goal is to be the financial partner of choice to leading life science companies and other institutions seeking to access non-dilutive capital, and we are actively looking to expand our portfolio. With the conclusion of the four recent transactions, PDL has deployed $368 million in capital in 2013 and $496 million in total to acquire new income generating assets to support our dividend payments." The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI]
--
WuXi PharmaTech (Cayman) Inc. Research Report
On November 4, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi PharmaTech's collection of patient-derived xenograft (PDX) mouse models. According to the Company, it has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries that have been developed in connection with the center's research and patient care. Dr. Ge Li, Chairman and CEO of WuXi, commented, "This agreement with the internationally renowned Mayo Clinic enables WuXi to provide the global research community with a unique single resource that will help advance cancer research through a more relevant and clinically directed approach." Li added, "We look forward to working with world-class organizations like Mayo Clinic to further strengthen our integrated, open-access R&D services platform, which enables anyone and any company to discover and develop new medicines for improved patient care." The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/df7b_WX]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article